Ampiroxicam , ≥98% , 99464-64-9
CAS NO.：99464-64-9
Empirical Formula: C20H21N3O7S
Molecular Weight: 447.46
MDL number: MFCD00866079
EINECS: 807-877-6
| Pack Size | Price | Stock | Quantity |
| 50MG | RMB79.20 | In Stock |
|
| 250MG | RMB239.20 | In Stock |
|
| 1G | RMB559.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 159-161?C |
| Density | 1.44±0.1 g/cm3(Predicted) |
| storage temp. | Sealed in dry,2-8°C |
| solubility | Chloroform (Slightly), Methanol (Slightly) |
| form | Solid |
| pka | 12.74±0.20(Predicted) |
| color | White to Off-White |
| CAS DataBase Reference | 99464-64-9(CAS DataBase Reference) |
Description and Uses
Ampiroxicam is a once-daily non-steroidal anti-inflammatory drug (NSAID) introduced in Japan. As a non-acidic ether carbonate prodrug of the widely used antiinflammatory agent, piroxicam, ampiroxicam is similar or more potent than piroxicam in suppressing carrageenan edema, ultraviolet erythema, traumatic edema, capillary permeability, acetic acid writhing, yeast algesia and yeast hyperthermia in many animals. Eioavailability studies in man show undetectable plasma levels of ampiroxicam indicating 100% conversion to piroxicam during absorption process. Ampiroxicam has been reported to have fewer side effects on the gastric mucosa than piroxicam.
antiinflammatory, analgesic
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264-P270-P301+P312-P330-P501 |
| Toxicity | LD50 orally in male, female rats: 1798, 747 mg/kg (Iijima) |
